Loading
CTT Pharmaceutical Holdings, Inc. Stock: price and insider trades · United States
US·Mcap US$3.3M
1 insider bought €3,884 of shares over the last 90 days, the latest filed 06 Oct 2026.
CTT Pharmaceutical Holdings, Inc.: what insiders have been doing
Every trade that managers of CTT Pharmaceutical Holdings, Inc. disclose to SEC (Form 4) is tracked on this page. In the past year (18 October 2025 to 18 October 2026), 16 filings came from 1 insider.
Not one open-market sale was filed. On the buying side, 1 insider reported 16 purchases totalling €13k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 senior executive and 1 chief executive among the declarants. One trade stands out by size: a purchase of €6,932 from CTT Pharmaceutical Holdings, Inc., disclosed on 24 November 2025.
Compared with its exchange (5,808 companies, median 19 filings), a count of 16 filings is below the norm. Our records for CTT Pharmaceutical Holdings, Inc. go back to 2023, with 60 purchases and no sales on the open market in total.
The most recent open-market purchase was published on 6 October 2026, 12 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
63
Thresholds
n/a
Buy Volume
€49,591
60 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleCTT Pharmaceutical Holdings, Inc.30 buys
Since the insiders bought
- +9.3%Entry US$0.05 · Close at T+30 US$0.06
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.06
Analyst consensus
Income statement
EBITDA-US$147.6k
Net income-US$155.9k0.0% margin
Valuation
P/Book50.0x
Beta0.64
Balance sheet & cash
Market capUS$3.3M
Total debtUS$18.8k
Free Cash Flow-US$79.8k
Debt / Equity75%
Profitability & ownership
ROE-357.0%
ROA-99.5%
% insiders50.3%
% institutions0.0%
Last declaration on 6 October 2026
Declarations63 total
3,700 shares@ US$0.0550.0063% mcap0.3% of flowCTTHSEC:0001035422-26-000016:0
Canonical exit: 4 Jan 2027 (T+90)
3,400 shares@ US$0.0550.0059% mcap0.2% of flowCTTHSEC:0001035422-26-000014:0
Canonical exit: 27 Dec 2026 (T+90)
10,100 shares@ US$0.0450.014% mcap0.6% of flowCTTHSEC:0001035422-26-000013:0
Canonical exit: 21 Dec 2026 (T+90)
10,900 shares@ US$0.0480.016% mcap0.7% of flowCTTHSEC:0001035422-26-000012:0
Canonical exit: 15 Dec 2026 (T+90)
3,500 shares@ US$0.050.0054% mcap0.2% of flowCTTHSEC:0001035422-26-000011:0
Canonical exit: 9 Dec 2026 (T+90)
9,800 shares@ US$0.04890.015% mcap0.6% of flowCTTHSEC:0001035422-26-000010:0
Canonical exit: 3 Dec 2026 (T+90)
3,500 shares@ US$0.0490.0053% mcap0.2% of flowCTTHSEC:0001035422-26-000008:0
Canonical exit: 29 Nov 2026 (T+90)
2,100 shares@ US$0.0550.0036% mcap0.1% of flowCTTHSEC:0001035422-26-000007:0
Canonical exit: 22 Nov 2026 (T+90)
11,500 shares@ US$0.0450.016% mcap0.6% of flowCTTHSEC:0001035422-26-000006:0
Canonical exit: 18 Nov 2026 (T+90)
10,000 shares@ US$0.0590.018% mcap0.7% of flowCTTHSEC:0001035422-26-000005:0
Canonical exit: 17 Nov 2026 (T+90)
1,800 shares@ US$0.0620.0035% mcap0.1% of flowCTTHSEC:0001035422-26-000004:0
Canonical exit: 12 Nov 2026 (T+90)
7,700 shares@ US$0.0650.016% mcap0.6% of flowCTTHSEC:0001035422-26-000001:0
Canonical exit: 5 Nov 2026 (T+90)
8,300 shares@ US$0.0550.6% of flowCTTHSEC:0001035422-25-000018:0
Canonical exit: 17 Mar 2026 (T+90)
200,000 shares@ US$0.0410.1% of flowCTTHSEC:0001035422-25-000017:0
Canonical exit: 18 Feb 2026 (T+90)
62,900 shares@ US$0.043.2% of flowCTTHSEC:0001035422-25-000016:0
Canonical exit: 18 Feb 2026 (T+90)
7,000 shares@ US$0.060.5% of flowCTTHSEC:0001035422-25-000015:0
Canonical exit: 29 Jan 2026 (T+90)
6,815 shares@ US$0.060.5% of flowCTTHSEC:0001035422-25-000014:0
Canonical exit: 22 Dec 2025 (T+90)
750,000 shares@ US$0.0438.3% of flowCTTHSEC:0001035422-25-000013:0
44,085 shares@ US$0.0452.5% of flowCTTHSEC:0001035422-25-000013:1
Canonical exit: 31 Oct 2025 (T+90)
15,800 shares@ US$0.0350.7% of flowShares AcquiredSEC:0001035422-25-000011:0
Canonical exit: 30 Oct 2025 (T+90)
8,000 shares@ US$0.030.3% of flowShares AcquiredSEC:0001035422-25-000010:0
Canonical exit: 6 Oct 2025 (T+90)
39,600 shares@ US$0.0251.2% of flowShares AcquiredSEC:0001035422-25-000009:0
Canonical exit: 24 Sept 2025 (T+90)
16,100 shares@ US$0.0250.5% of flowShares AcquiredSEC:0001035422-25-000008:0
Canonical exit: 21 Sept 2025 (T+90)
54,798 shares@ US$0.0251.9% of flowCTTHSEC:0001035422-25-000007:0
Canonical exit: 11 Sept 2024 (T+90)
82,158 shares@ US$0.055.2% of flowCTTHSEC:0001035422-25-000006:0
Canonical exit: 7 Sept 2025 (T+90)
25 of 63 declarations
About CTT Pharmaceutical Holdings, Inc.
CTT Pharmaceutical Holdings, Inc. is a company focused on the development and commercialization of pharmaceutical products. It is listed on NASDAQ under the ticker CTT.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
